Peculiarities of neuroprotective therapy in women with acute ischemic stroke

Authors

DOI:

https://doi.org/10.14739/2310-1210.2020.4.208352

Keywords:

stroke, women, neuroprotection, edaravone

Abstract

 

There are significant differences between the course of acute ischemic stroke (AIS) in men and women. On average, women with AIS have a more pronounced degree of neurological disorders, higher mortality and disability. However, carotid procedures and thrombolytic therapy are performed less frequently in women than in men, requiring the search for alternative therapies for the treatment of AIS in women (neuroprotection).

Aim. To investigate the effectiveness of a combination therapy with edaravone as a neuroprotector in women with AIS.

Materials and methods. A prospective study enrolled 48 women with AIS, divided into two groups. The first group patients (n = 36) were treated with edaravone 30 mg twice daily, intravenously. Neuroprotectors were not used in the control group (n = 12). Clinical-instrumental and neurological examinations (Glasgow Coma Scale (GCS), FOUR, NIHSS, neurospecific enolase (NSE) levels) were performed in all the patients.

Results. An analysis of GCS scores showed a positive trend in most patients of both groups, with no difference between the groups. Thus, the mean GCS score in the main group increased from 11.84 ± 2.62 to 13.87 ± 0.94 points against 11.69 ± 3.15 to 13.31 ±1.78 in the control group (P > 0.05). The FOUR score showed that in group 1, the level of consciousness recovered more rapidly from the 5th day and up to 9–10 days of treatment it was: in the edaravone group – 15.47 ± 0.85 points, in the control group – 13.62 ± 1.19 points (P < 0.05). The level of NSE was higher than normal in all the women, with the highest level in patients of the control group, in whom it increased 10-fold (from 9.2 to 96.4 ng/ml, P < 0.01). Later on, there was a rapid decrease in NSE level in group 1, while the level of NSE did not reach the reference values (P < 0.05) until day 10 of treatment in the control group.

Conclusions. The administration of edaravone in women with AIS resulted in favorable outcomes even in the acute period of the disease. The use of edaravone was significantly effective on the FOUR scale and by the dynamics of NSE levels. Further studies are needed to clarify the role and place of edaravone in the ischemic stroke intensive care setting.

 

References

  1. Tomaszewski, M., Topyła, W., Kijewski, B. G., Miotła, P., & Waciński, P. (2019). Does gender influence the outcome of ischemic heart disease? Menopausal Review, 18(1), 51-56. https://doi.org/10.5114/pm.2019.84158
  2. Christensen, H., Bentsen, L., & Christensen, L. (2016). Update on specificities of stroke in women. Presse medicale (Paris, France: 1983), 45(12 Pt. 2), e409-e418. https://doi.org/10.1016/j.lpm.2016.10.005
  3. Di Carlo, A., Lamassa, M., Baldereschi, M., Pracucci, G., Basile, A. M., Wolfe, C. D., Giroud, M., Rudd, A., Ghetti, A., Inzitari, D., & European BIOMED Study of Stroke Care Group. (2003). Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke, 34(5), 1114-1119. https://doi.org/10.1161/01.STR.0000068410.07397.D7
  4. Girijala, R. L., Sohrabji, F., & Bush, R. L. (2017). Sex differences in stroke: Review of current knowledge and evidence. Vascular medicine, 22(2), 135-145. https://doi.org/10.1177/1358863X16668263
  5. Lundberg, G. P., & Volgman, A. S. (2016). Burden of stroke in women. Trends in Cardiovascular Medicine, 26(1), 81-88. https://doi.org/10.1016/j.tcm.2015.04.010
  6. Triches, C., Schaan, B. D., Gross, J. L., & Azevedo, M. J. (2009). Macrovascular diabetic complications: clinical characteristics, diagnosis and management. Arquivos brasileiros de endocrinologia e metabologia, 53(6), 698-708. https://doi.org/10.1590/s0004-27302009000600002
  7. Appelros, P., Stegmayr, B., & Terént, A. (2009). Sex Differences in Stroke Epidemiology. Stroke, 40(4), 1082-1090. https://doi.org/10.1161/strokeaha.108.540781
  8. Jerath, N. U., Reddy, C., Freeman, W. D., Jerath, A. U., & Brown, R. D. (2011). Gender Differences in Presenting Signs and Symptoms of Acute Ischemic Stroke: A Population-Based Study. Gender Medicine, 8(5), 312-319. https://doi.org/10.1016/j.genm.2011.08.001
  9. Labiche, L. A., Chan, W., Saldin, K. R., & Morgenstern, L. B. (2002). Sex and acute stroke presentation. Annals of emergency medicine, 40(5), 453-460. https://doi.org/10.1067/mem.2002.128682
  10. Alamowitch, S., Eliasziw, M., Barnett, H. J., North American Symptomatic Carotid Endarterectomy Trial (NASCET), ASA Trial Group, & Carotid Endarterectomy (ACE) Trial Group. (2005). The risk and benefit of endarterectomy in women with symptomatic internal carotid artery disease. Stroke, 36(1), 27-31. https://doi.org/10.1161/01.STR.0000149622.12636.1f
  11. Moretti, A., Ferrari, F., & Villa, R. F. (2015). Neuroprotection for ischaemic stroke: current status and challenges. Pharmacology & therapeutics, 146, 23-34. https://doi.org/10.1016/j.pharmthera.2014.09.003
  12. Watanabe, K., Tanaka, M., Yuki, S., Hirai, M., & Yamamoto, Y. (2018). How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? Journal of clinical biochemistry and nutrition, 62(1), 20-38. https://doi.org/10.3164/jcbn.17-62
  13. Kern, R., Nagayama, M., Toyoda, K., Steiner, T., Hennerici, M. G., & Shinohara, Y. (2013). Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovascular diseases, 35(5), 402-418. https://doi.org/10.1159/000351753
  14. Kaste, M., Murayama, S., Ford, G. A., Dippel, D. W., Walters, M. R., Tatlisumak, T., & MCI-186 study group. (2013). Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovascular diseases, 36(3), 196-204. https://doi.org/10.1159/000353680
  15. Yamaguchi, T., Awano, H., Matsuda, H., Tanahashi, N., & PROTECT4.5 Investigators. (2017). Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). Journal of stroke and cerebrovascular diseases, 26(4), 756-765. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.10.011
  16. Yang, J., Cui, X., Li, J., Zhang, C., Zhang, J., & Liu, M. (2015). Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. Developmental neurorehabilitation, 18(5), 330-335. https://doi.org/10.3109/17518423.2013.830153
  17. Edaravone Acute Infarction Study Group. (2003). Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovascular diseases, 15(3), 222-229. https://doi.org/10.1159/000069318
  18. Kimura, K., Aoki, J., Sakamoto, Y., Kobayashi, K., Sakai, K., Inoue, T., Iguchi, Y., & Shibazaki, K. (2012). Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients - A preliminary study. Journal of the neurological sciences, 313(1-2), 132–136. https://doi.org/10.1016/j.jns.2011.09.006
  19. Manwani, B., & McCullough, L. D. (2019). On the Basis of Sex. Stroke, 50(9), 2285-2287. https://doi.org/10.1161/STROKEAHA.119.025955

Downloads

How to Cite

1.
Halushko OA, Trischynska MA, Vityuk AD. Peculiarities of neuroprotective therapy in women with acute ischemic stroke. Zaporozhye Medical Journal [Internet]. 2020Jul.22 [cited 2026May21];22(4). Available from: https://zmj.zsmu.edu.ua/article/view/208352

Issue

Vol. 22 No. 4 (2020)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons